Company intelligence / Profile preview

Kalapharm

San Jose, California, USA

Ownership: Private
Development stage: Other

Overview

Kalapharm was a biotechnology company specializing in the development of half-life extension technologies for biopharmaceuticals. The company's proprietary platform focused on advanced polymer conjugation, particularly PEGylation, to improve the pharmacokinetic and pharmacodynamic properties of therapeutic proteins and peptides. These modifications were designed to increase drug stability, reduce immunogenicity, and allow for less frequent dosing. In 2005, Kalapharm was acquired by Nektar Therapeutics, a leader in drug delivery systems, to integrate its specialized conjugation expertise into Nektar's broader portfolio.

Modalities: PeptidesProteinPolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on Kalapharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalapharm.

Explore the full profile